Effects of Growth Hormone and Pioglitazone in Obese Adults with Impaired Glucose Tolerance
Author Information
Author(s): Attallah Hamdee, Friedlander Anne L, Nino-Murcia Matilde, Hoffman Andrew R
Primary Institution: Wayne State University
Hypothesis
The combination of growth hormone and pioglitazone attenuates GH-induced increases in glucose concentrations, reduces visceral adipose tissue, and improves insulin sensitivity over time.
Conclusion
The addition of pioglitazone to growth hormone treatment reduced visceral fat and insulin resistance in obese adults with impaired glucose tolerance.
Supporting Evidence
- GH treatment resulted in significant reductions in visceral fat area.
- Insulin resistance declined with pioglitazone treatment.
- Combination treatment with GH and PIO improved insulin sensitivity.
Takeaway
This study found that using two medications together can help people who are overweight and have trouble with blood sugar levels by reducing belly fat and making their bodies better at using insulin.
Methodology
Randomized, double-blind, placebo-controlled, 2 × 2 factorial design over 40 weeks.
Potential Biases
The study was not designed to detect statistically significant differences in side effects between groups.
Limitations
The study did not directly measure the likelihood of developing diabetes as an outcome.
Participant Demographics
Participants were 62 abdominally obese adults aged 40–75 with impaired glucose tolerance.
Statistical Information
P-Value
p = 0.02
Confidence Interval
95% CI −49.9 to −6.3 cm2
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website